Repatha dose
Pro Research Analysisby 
Searched over 200M research papers for "repatha dose"
Consensus Meter
Repatha (Evolocumab) Dosage and Efficacy
Introduction to Repatha (Evolocumab)
Repatha, also known by its generic name evolocumab, is a monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9). This drug is primarily used to lower low-density lipoprotein cholesterol (LDL-C) levels in patients with hyperlipidemia, including those with familial hypercholesterolemia and those who are statin-intolerant .
Dosage Recommendations for Repatha
Repatha is administered via subcutaneous injection. The recommended dosages are either 140 mg every two weeks or 420 mg once a month . These dosing schedules have been shown to be effective in significantly reducing LDL-C levels in various patient populations, including those with primary hypercholesterolemia, mixed dyslipidemia, and familial hypercholesterolemia .
Efficacy in Lowering LDL-C Levels
Clinical trials have demonstrated that Repatha can reduce LDL-C levels by approximately 50-60% from baseline when added to statin therapy . This reduction is consistent across different patient groups, including those who are statin-intolerant and those with homozygous familial hypercholesterolemia . In patients with homozygous familial hypercholesterolemia, Repatha has shown a treatment difference of about 30% versus placebo when added to statins with or without ezetimibe.
Long-term Efficacy and Safety
The long-term efficacy and safety of Repatha have been evaluated in trials lasting up to 76 weeks. These studies indicate that the drug is well-tolerated and maintains its efficacy over extended periods . Additionally, Repatha has been shown to significantly reduce other lipid parameters, including total cholesterol, non-HDL cholesterol, apoprotein B, and lipoprotein(a).
Clinical Applications and Patient Eligibility
Repatha is particularly beneficial for patients who cannot achieve their LDL-C goals with statins alone or who are statin-intolerant. It is approved for use in patients with heterozygous and homozygous familial hypercholesterolemia and those with clinical atherosclerotic cardiovascular disease where LDL-C lowering is insufficient . Approximately 13% of patients with heterozygous familial hypercholesterolemia and cardiovascular disease, who have LDL-C levels greater than 100 mg/dL despite maximal-tolerated LDL-C-lowering therapy, are eligible for Repatha treatment.
Conclusion
Repatha (evolocumab) is a potent PCSK9 inhibitor that offers a significant reduction in LDL-C levels for patients with hyperlipidemia, including those with familial hypercholesterolemia and those who are statin-intolerant. Administered at dosages of 140 mg every two weeks or 420 mg once a month, Repatha has proven to be effective and well-tolerated in both short-term and long-term studies. This makes it a valuable adjunctive treatment for patients struggling to manage their cholesterol levels with traditional therapies alone.
Sources and full results
Most relevant research papers on this topic